New 7-item #mentalhealth quality of life questionnaire (MHQoL-7D) by Krugten et al is now published open access link.springer.com/article/10.100…

The burden posed by a disease not only affects the sufferers, but also their relatives. It is important to adopt a societal viewpoint when deciding which kind of costs and #healthbenefits to include in an economic evaluation. Read our #blogpost here😊 ➡️bit.ly/3wWF3t8

'Fabrikanten wachten om verbeteringen door te voeren tot het patent verlopen is. Patenten remmen zo innovatie.' knack.be/nieuws/belgie/…

Performance of the EQ-5D-5L Plus Respiratory Bolt-On in the Birmingham Chronic Obstructive Pulmonary Disease Cohort Study valueinhealthjournal.com/article/S1098-…

Modeling the Cost-Utility of Treatment Sequences for Multiple Sclerosis valueinhealthjournal.com/article/S1098-…

Opportunity: EsCHER awards scholarships to support excellent students from non-EEA countries for the master programmes Health Economics and Health Economics, Policy & Law, starting for 2022-2023 academic year. For more information on EsCHER please visit eur.nl/escher

"Ignoring the costs of non-medical consumption results in an underestimation of the costs of life prolonging interventions." Our new paper, with Klas Kellerborg, @pietervbaal and @werner_brouwer. Erasmus Centre for Health Economics Rotterdam ESHPM ErasmusUniRdam sciencedirect.com/science/articl…

Prof Rutten-van Molken shows that the average net benefit of personalized medicines might be negative, but that preventing AE’s with diagnostics can save money and increase health #hecopermed HEcoPerMed ESHPM ErasmusUniRdam

Morgen verdedigt Brenda Leeneman haar proefschrift, getiteld: ‘Evidence-Based Decision Making on #Drug #Reimbursement in #Melanoma. Using real-world evidence to complement evidence from randomized controlled trials’. Veel succes Brenda! eur.nl/eshpm/evenemen…

De podcast is tot stand gekomen door onze collega Sonja Cloosterman samen met Matthijs Versteegh en Dennis Japink: omny.fm/shows/waardevo…

Now live at #ISPOREurope the HEcoPerMed results on modelling personalized medicine. Topics include tumor agnostic treatments, DPYD testing to avoid AE’s and testing for MODY

Reminder: EsCHER awards scholarships to support excellent students from non-EEA countries for the master programmes Health Economics and Health Economics, Policy & Law, deadline for submission 31/1/22. For more information on EsCHER please visit eur.nl/escher

🎉We are happy to announce that we have sent out our 7th #COMPAREU #newsletter 😊Learn more about our work on the project, the COMPAR-EU platform development, how we involve patients, how we interpret the effectiveness of self-management and much more! self-management.eu/compar-eu-news…

We staan als Erasmus Universiteit achter je, Marion. Bedreiging van wetenschappers is onaanvaardbaar. Bedreiging van wie dan ook is onacceptabel. Recent hebben we met de Nederlandse rectoren een aanpak bedreiging en intimidatie aangenomen. universiteitenvannederland.nl/files/document…

Effectiveness and Cost-Effectiveness of 360 Disease-Modifying Treatment Escalation Sequences in Multiple Sclerosis valueinhealthjournal.com/article/S1098-…

iMTA and Erasmus MC collaborated in the field of #multiplesclerosis and recently published results in ISPORJournals: analysis of 360 DMT treatment sequences shows that the most effective sequence is not the most cost-effective sequence. sciencedirect.com/science/articl…

iMTA has launched a completely new website with a publication database, easier registration of our questionnaires for HTA, integration of our HEOR course and daily HTA news. imta.nl

Does underlying health matter for QALYS lost due to Covid? Using estimates per disease-group we find 3.9 QALYS lost per Covid-death for men and 3.5 for women in NL in 2020. About half of unadjusted estimates. New paper with @pietervbaal and Frederique Ram sciencedirect.com/science/articl…

The Net Benefit of Personalized Medicine: A Systematic Literature Review and Regression Analysis by the HEcoPerMed consortium valueinhealthjournal.com/article/S1098-…

NEW PUBLICATION Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options Rositsa Koleva-Kolarova James Buchanan iMTA News Channel HEcoPerMed #healtheconomics #personalisedmedicine link.springer.com/article/10.100…